FILE PHOTO: A child is administered a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) pediatric vaccine, in San Jose, Costa Rica February 23, 2022. REUTERS/Mayela Lopez
(Reuters) - A third dose of Pfizer Inc and BioNTech's COVID vaccine produced significant protection against the Omicron variant in healthy children aged between 5 and 11 years in a trial, the companies said on Thursday.
Blood serum analysis of a few pediatric participants who received a booster dose in the study showed a 36-fold increase in Omicron neutralizing antibodies, the drugmakers said.
Already a subscriber? Log in.
Subscribe now for a chance to win your dream holiday!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
